Jefferies Financial Group’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
Jefferies Financial Group's ACRS Position: Q3 2026 in Review
Jefferies Financial Group sold out of Aclaris Therapeutics (ACRS) in Q3 2026, closing a stake of 11,000 shares — an estimated $58.2K sold.
Jefferies Financial Group first reported a position in ACRS in Q1 2023 and held it in 14 quarters. The position peaked at $3.37M in Q1 2023. 166 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- Jefferies Financial Group reported no remaining Aclaris Therapeutics position as of Q3 2026 after selling out during the quarter.
- Jefferies Financial Group sold 11,000 Aclaris Therapeutics shares in Q3 2026, an estimated $58.2K.
- Jefferies Financial Group first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 14 quarters.
- Jefferies Financial Group's Aclaris Therapeutics position peaked at $3.37M in Q1 2023.
- 166 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.